Member Info for sitiain

Do we know how many of the drugs sold are repeat prescriptions please. Doing some reading. Assuming most will be as the condition doesn't go away. I can't find much detail on this if anyone could help

thank you

Could someone help, please? trying to get my head around this company and its product. How much of this growth is renewable? ie if you sell to one person, I assume they take it for a prolonged period? So what do we think percentage-wise will be repeat prescriptions? I hope I am not being lazy here, I need to do a deeper dive. Just trying to understand the need for treatment, I assume iron deficiency is just an ongoing problem? Are there any articles covering this, please?

Thank you for anyone time in advance, much appreciated.

Dipped my toe again here last month due to the tech . It’s hopeless

They need a complete revamp

More cash

New board

Why do I bother with AIM

They will need money again come the new year and what is going to change . 🤷‍♂️The prostrate test is the only chance and they can’t sell any . Need a big swinging divk in charge . They won’t be able to attract one . Best sell tech to pharma because they will be picking not up for pennies soon as it goes bust

XBI very weak with rates pushing higher in the States certainly not helping here . Very risk off . Nothing to encourage new buyers or anyone topping up . ( Let’s be honest the believers are all in ) . Difficult times . Let’s hope the science gets in the news because at the moment the investment audience is far too small

I can’t help but think if this was America. They would have taken this tech and raised 100 mio dollars . Price would not matter . Build a moat/ manufacturing/ PR/ sales . Beg steal borrow to get on this prostrate national test and get the bloody thing verified . A big pharma would swoop on this and pay billions if it was set up right and s good as they say it is( who knows ).

I’ve been actually hammered this year . Avacta, these idiots and shield . Stupid stupid me . I was out at 15 pence and will only come back if they get on this nhs screening test . Trouble is I think they get bullied by

Initial big holders that are scared of dilution . Needs to done with at least 2/3 years cash run way so everyone’s not running around panicking about share price / future raises than getting the job done . I hope This works fr the many grumpy old men like me that have no way of telling if they have prostrate cancer or not .Why only raise 10 now . It be was bloody 40 pence a few weeks ago and they knew they were selling bigger all

I see the new holders flipping for a few percent profit . I can’t imagine anyone else selling after such big paper losses . I wonder if going with a lower dose and sticking with it may have saved time with these trails .The more dox surely the more scrutiny and risk . Lower doss , more cycles will the patient was observed surely would be easier to get through 🤷‍♂️. Ignore my rants I’ve still livid at myself for risking so much here . I’m at that. Why did I ever both investing in shares stage of my life .Advise to others . Buy index funds and if you want to trade . Trade US stocks . Loads of liquidity, cheaper . This AIM just seems broken . Good luck to all.

Could someone explain how I no apply please ?

Thank you

Good luck to all.having been a holder in Oxford Bio ( 95 per cent efficient Prostrate test ) , hammered. Shield therapeutics.. hammered and a real believer here but just need to preserve capital. Good luck to all I hope it works for longs and patients.

This London market I don't know. I think there is a wider issue here with these small companies there just doesn't seem to be capital or maybe it's the quality of management. Bios can go wrong. I always suspected this will take longer than the bulls thought but got overly excited perhaps. Will keep an eye out and I hope for the bulls sake today's sell is something I regreat

NIce letter, I see this, I think was played at the Super Bowl too sponsored by Astra Zenica

I am out presently with this stock after taking a huge loss. Want to get back in but awaiting some kind of plan from the company and maybe some more documentation proving this test and what it can do.

Absolutely flabbergasted as its potential but need a plan and assurances its not all rubbish

https://cancersupport360.com/getbodychecked

$MRK seeking M&A deals up to $15 bil in order soften the blow from loss of exclusivity of Keytruda in 2028,

Keytruda was $25 bil of $60.1 bil in sales in 2023 so it's a big hole to fill,

MRK paid $10.8 bil for Prometheus last yr & $11 bil for Acceleron in 2021,

In the last 3 months MRK also paid $610 mil for Caraway and $680 mil for $HARP

So , are we suggesting the PSE test s not taken seriously due to a lack of data . I’ve made a mistake here and thought it was thus my big holding and disastrous week . Could a BUPA turn around and agree terms for a test ? Or is that a pipe dream . ? Surely that would re- rate everything . How far off being taken seriously is this test do we think. We all know how expensive trails are . Really annoyed at myself here for getting over excited again. Appreciate any views thank you

65000 PSA tests a day in the states at 55 percent accuracy ( what’s the point ?

NHS don’t bother testing everyone because of the accuracy . They very likely will with this dynamic

Have you any idea how many over 50 s pay privately for blood tests these days . Prostrate not included again due to lack of accuracy.

Sure today was disappointing. Are you actually serious no large pharma would be interested in rolling the test out ? It’s worth a fortune surely

Bit disappointed which I think is my fault/naivety over a time scale.Would have liked to get a better understanding of what is actually next concerning trail design/time scale and cost. My other involvements with trials involve hundreds of patients. I know this is different but I am not sure they can shortcut that much with regard to time and cost. Lots of moving parts with regard to patient history, and different diseases. I will await more information and it's all very exciting. I was just expecting more.

Well I've emailed dhsc.publicenquiries@dhsc.gov.uk

and Prostrate Cancer Charity and the company to ask why they/we are not involved. It would be an enormous waste of time and money not to include OBD so would ask others to kick up a fuss.

Appreciate the information on the board its very helpful and let's all keep it this way. Many thanks

Very kind thank you

May I ask please , what time line and development are we expecting from our test ? Also is it manufactured externally .

Trying to educate myself here as I build a position . What approval are we waiting for too please ? What would have to happen. For the nhs to use the test . I read PSA testing isn’t routinely done due to its inaccuracy. The potential here is of course very unusual.

Are we worried about any other new tests perhaps .

Thank you for anyone’s time , much appreciated

Dr Arrivo joins Oxford BioDynamics from CellCarta Biosciences (formerly Caprion) where he spent five years in Business Development, as Senior Director and Vice President. Prior to that he was at Biodesix and Ventana Medical Systems. Before then, he spent four years at Pfizer in various R&D roles and he began his career at Merck & Co., Inc. as a Senior Project Scientist following several academic research positions. Dr Arrivo holds a Bachelor's degree in Chemistry from the University of Eastern Illinois, and a Master's degree in Synthetic Organic and Inorganic Chemistry and Ph.D. in Physical Chemistry from Northwestern University. He completed Postdoctoral studies in Physical Chemistry at Columbia University.

I own ACHL (UK pharma) Nasdaq MC 35 mio cash 143 mio

DTIL Nasdaq MC 49 mio cash 138mio

Both heavily shorted . They are not as exciting as Dest, or are anywhere near them regarding drug development but ..Shows that a nasdaq list is hardly favourable in my opinion to their market cap.

I hear the same argument with AVACTA and OBD.Both would be heavily shorted if listed on the Nasdaq.

The value will take care of itself one day but probably only when they are bought out.

Tirupati Graphite

@Tirupatiuk

·

1h

#TGR a leading alternative Ex-China current producer of NF #Graphite with key differentiators.

At 🇲🇬 a focus on Sustainability & #TGR has achieved 45% operational margins, industry low capital intensity & Opex, and targeting similar for 🇲🇿 - selling to growing ex-China markets

Company worth $53m gets $25m up front + $80m equity investment @ $365m valuation $CLLS $AZN